LivaNova PLC (LIVN) KPIs and segments
Close on Nov 18, 2026Market cap $5.21BP/E 27.9Yield –
KPIs & segments
Operating metrics and segments that drive LivaNova's business
LivaNova's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
LivaNova's fiscal year ends December 31 — Q2 2026 = CQ2 2026 (calendar quarter).
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardiopulmonary($M)3 | 222 | 209 | 207 | 203 | 199 | 176 | 182 | 172 | 174 | 156 | 165 | 149 | |
Rest of World($M) | 86.8 | 82.1 | 77.3 | 81.2 | 79.0 | 71.0 | 69.5 | 68.8 | 70.3 | 64.4 | 58.6 | 61.2 | |
United States($M) | 72.8 | 69.3 | 71.8 | 71.9 | 71.2 | 60.8 | 64.5 | 62.5 | 64.9 | 50.6 | 60.5 | 52.3 | |
Europe($M) | 62.0 | 57.3 | 57.4 | 50.1 | 49.0 | 44.5 | 47.6 | 40.9 | 38.6 | 40.9 | 46.2 | 35.5 | |
Neuromodulation($M)3 | 167 | 152 | 153 | 150 | 152 | 139 | 138 | 140 | 143 | 134 | 137 | 129 | |
United States($M) | 127 | 115 | 120 | 118 | 117 | 108 | 111 | 113 | 112 | 106 | 106 | 102 | |
Rest of World($M) | 20.5 | 18.0 | 15.5 | 16.6 | 16.7 | 15.4 | 13.1 | 15.0 | 15.6 | 14.5 | 14.1 | 13.7 | |
Europe($M) | 19.9 | 18.3 | 17.6 | 14.5 | 17.7 | 15.2 | 14.0 | 11.9 | 15.6 | 13.4 | 16.4 | 12.7 | |
Earlier reporting (last reported 2023)1 | |||||||||||||
United States($M) | 199 | 185 | 191 | 190 | 188 | 169 | 175 | 180 | 180 | 161 | 173 | 162 | |
Rest of World($M) | 109 | 102 | 94.4 | 99.6 | 97.3 | 88.0 | 85.1 | 85.5 | 87.8 | 80.0 | 74.4 | 76.4 | |
Europe($M) | 81.8 | 75.7 | 75.0 | 67.7 | 66.8 | 59.7 | 61.6 | 52.8 | 51.3 | 54.3 | 62.6 | 48.1 | |
Neuromodulation($M) | 60.9 | 44.2 | 50.9 | 56.2 | 56.0 | 52.4 | 44.3 | 49.5 | |||||
Cardiopulmonary($M) | 28.2 | 30.1 | 27.5 | 24.7 | 31.4 | 24.7 | 20.8 | 21.7 | |||||
Neuromodulation($M) | 152 | 138 | 138 | 137 | 137 | 126 | 121 | 128 | 131 | 124 | |||
Cardiopulmonary($M) | 124 | 108 | 103 | 105 | 104 | 91.4 | 91.2 | 91.3 | 87.1 | 79.6 | |||
Neuromodulation($M) | -7.78 | -8.84 | -4.85 | -4.74 | -4.22 | -2.03 | -1.86 | -1.38 | -0.73 | -0.28 | -0.11 | -0.60 | |
Cardiopulmonary($M) | -12.5 | -10.4 | -21.1 | -9.50 | -8.77 | -5.17 | -9.43 | -7.38 | -7.53 | -3.75 | -10.9 | -4.14 | |
Cardiopulmonary($M) | 1,051 | 1,046 | 1,045 | 1,019 | 1,014 | 940 | 901 | 967 | 934 | 943 | 962 | ||
Neuromodulation($M) | 652 | 650 | 640 | 640 | 638 | 642 | 641 | 635 | 640 | 652 | 647 | ||
Earlier reporting (last reported 2023)1 | |||||||||||||
28 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-05.
See a number that looks wrong?